# Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of Hepatocellular Carcinoma (HCC)

> **NCT01381211** · PHASE2 · TERMINATED · sponsor: **University Hospital, Ghent** · enrollment: 72 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** TACE-DEB
- **DRUG:** 90Y-RE

## Key facts

- **NCT ID:** NCT01381211
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-09
- **Primary completion:** 2018-03
- **Final completion:** 2020-03
- **Target enrollment:** 72 (ACTUAL)
- **Why stopped:** based on interim analysis results
- **Last updated:** 2022-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01381211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01381211, "Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01381211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*